Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina
Research foundation in Buenos Aires
Juncal 2222, C1125 ABD, Buenos Aires
About Fundación CENIT para la Investigación en Neurociencias
"Fundación para la investigación en Neurociencias"
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
22
Eli Lilly and Company
7
CureVac
1
Janssen Research & Development, LLC
1
Loxo Oncology, Inc.
1
Pfizer
1
Clinical Trials at Fundación CENIT para la Investigación en Neurociencias
During the past decade, Fundación CENIT para la Investigación en Neurociencias conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 10 clinical trials were completed, i.e. on
average, 34.5% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 7 clinical trials were completed. i.e. 43.8%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
2013-04-03
2025-04-03
Active, not recruiting
1,487
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
2013-06-27
2020-11-12
Completed
2,877
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
2013-12-13
2023-11-30
Active, not recruiting
921
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
2015-03-31
2020-12-07
Completed
1,202
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
2015-06-11
2021-02-17
Completed
1,021
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
2015-06-23
2021-08-31
Completed
902
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
2017-09-20
2030-03-06
Active, not recruiting
382
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Fundación CENIT para la Investigación en Neurociencias" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "Eli Lilly and Company" with 7 trials
sponsored, "CureVac" with 1 trials sponsored, "Janssen Research & Development, LLC" with 1 trials sponsored and "Loxo Oncology, Inc."
with 1 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Fundación CENIT para la Investigación en Neurociencias"
#1 collaborator was "Chugai" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Exelixis" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Fundación CENIT para la Investigación en Neurociencias
According to Clinical.Site data, the most researched conditions in "Fundación CENIT para la Investigación en Neurociencias" are
"Non-Small Cell Lung Cancer" (5 trials), "Breast Neoplasms" (4 trials), "Early Breast Cancer" (3 trials), "Neoplasm Metastasis" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Fundación CENIT para la Investigación en Neurociencias" in a lesser frequency.
Clinical Trials Intervention Types at Fundación CENIT para la Investigación en Neurociencias
Most popular intervention types in "Fundación CENIT para la Investigación en Neurociencias" are "Drug" (32 trials), "Procedure" (2 trials), "Radiation" (2 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (9 trials), "Placebo" (8 trials), "Paclitaxel" (6 trials), "Abemaciclib" (5 trials) and "Carboplatin" (5 trials). Other intervention names were less common.
Clinical Trials Genders at Fundación CENIT para la Investigación en Neurociencias
The vast majority of trials in "Fundación CENIT para la Investigación en Neurociencias" are
32 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at Fundación CENIT para la Investigación en Neurociencias
Currently, there are NaN active trials in "Fundación CENIT para la Investigación en Neurociencias".
undefined are not yet recruiting,
12 are recruiting,
11 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 8 completed trials in Fundación CENIT para la Investigación en Neurociencias,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Fundación CENIT para la Investigación en Neurociencias, 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 29 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 0 trials that are defined as “Not Applicable".